MedDataX Logo

Fluorescence Imaging in Finding Tumors in Patients With Kidney Tumors

NCT ID: NCT01281488

Last Updated: 2017-10-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-10-20

Study Completion Date

2017-10-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Using fluorescence imaging may determine the extent of kidney tumors and help in planning surgery.

PURPOSE: This phase I trial is studying the best way to give indocyanine green (ICG) fluorescence imaging in finding tumors in patients with kidney tumors

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To determine the optimal dose of ICG fluorescence for visualization using the SPY scope with near infrared (NIR) imaging technology on the da Vinci Surgical System to detect renal cortical tumors and to assist in their removal.

SECONDARY OBJECTIVES:

I. To observe and report peri-operative outcomes, including but not limited to the following observations: positive surgical margin rate, correlation of the ICG and NIR imaging technology with intraoperative ultrasound imaging and preoperative imaging, incidence of adverse events, estimated blood loss, blood transfusion rate, length of stay, time of operation, utility of ICG and NIR imaging technology to assist in localization of renal hilar structures, utility of ICG and NIR imaging technology to assist in localization of the renal mass, warm renal ischemia time measurements, the feasibility of selective renal arterial clamping with the ICG and NIR imaging technology, cost analysis retrospective comparisons to patients who underwent similar surgical procedures without the use of ICG and NIR imaging technology, the overall effect of ICG and NIR imaging technology on postoperative renal function, and determination of possible future technique variations using the ICG and NIR imaging technology to improve nephron sparing surgery.

OUTLINE: This is a dose-escalation study. Patients undergo NIR fluorescence imaging with ICG on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.

After completion of study treatment, patients are followed up at 1-2 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Recurrent Renal Cell Cancer Stage I Renal Cell Cancer Stage II Renal Cell Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment 1 (fluorescence imaging and surgery)

Patients undergo NIR fluorescence imaging with ICG and an additional 0.018 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.

Group Type EXPERIMENTAL

fluorescence imaging

Intervention Type PROCEDURE

Undergo NIR fluorescence imaging with ICG on the da Vinci surgical system

laparoscopic surgery

Intervention Type PROCEDURE

Undergo standard approach robot-assisted laparoscopic partial nephrectomy

indocyanine green

Intervention Type DRUG

Given IV

Treatment 2 (fluorescence imaging and surgery)

Patients undergo NIR fluorescence imaging with ICG and an additional 0.036 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.

Group Type EXPERIMENTAL

fluorescence imaging

Intervention Type PROCEDURE

Undergo NIR fluorescence imaging with ICG on the da Vinci surgical system

laparoscopic surgery

Intervention Type PROCEDURE

Undergo standard approach robot-assisted laparoscopic partial nephrectomy

indocyanine green

Intervention Type DRUG

Given IV

Treatment 3 (fluorescence imaging and surgery)

Patients undergo NIR fluorescence imaging with ICG and an additional 0.07 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.

Group Type EXPERIMENTAL

fluorescence imaging

Intervention Type PROCEDURE

Undergo NIR fluorescence imaging with ICG on the da Vinci surgical system

laparoscopic surgery

Intervention Type PROCEDURE

Undergo standard approach robot-assisted laparoscopic partial nephrectomy

indocyanine green

Intervention Type DRUG

Given IV

Treatment 4 (fluorescence imaging and surgery)

Patients undergo NIR fluorescence imaging with ICG and an additional 0.14 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.

Group Type EXPERIMENTAL

fluorescence imaging

Intervention Type PROCEDURE

Undergo NIR fluorescence imaging with ICG on the da Vinci surgical system

laparoscopic surgery

Intervention Type PROCEDURE

Undergo standard approach robot-assisted laparoscopic partial nephrectomy

indocyanine green

Intervention Type DRUG

Given IV

Treatment 5 (fluorescence imaging and surgery)

Patients undergo NIR fluorescence imaging with ICG and an additional 0.21 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.

Group Type EXPERIMENTAL

fluorescence imaging

Intervention Type PROCEDURE

Undergo NIR fluorescence imaging with ICG on the da Vinci surgical system

laparoscopic surgery

Intervention Type PROCEDURE

Undergo standard approach robot-assisted laparoscopic partial nephrectomy

indocyanine green

Intervention Type DRUG

Given IV

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fluorescence imaging

Undergo NIR fluorescence imaging with ICG on the da Vinci surgical system

Intervention Type PROCEDURE

laparoscopic surgery

Undergo standard approach robot-assisted laparoscopic partial nephrectomy

Intervention Type PROCEDURE

indocyanine green

Given IV

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

laparoscopy-assisted surgery surgery, laparoscopic

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with a computed tomography (CT) scan or magnetic resonance imaging (MRI) on preoperative assessment showing evidence of a renal cortical tumor; the renal tumor must be stage T1a/bT2
* Due to concerns of surgical and anesthetic effects on the fetus, women of child bearing age who are considered to still be fertile must undergo a urine pregnancy test prior to inclusion in the study; only women with negative urine pregnancy tests prior to surgery will be included; if a women is found to have a positive urine pregnancy test, surgery and potential inclusion in the study will be deferred until after delivery of the baby; should a woman become pregnant or suspect that she is pregnant prior to surgical management, she should inform her treating physician immediately; although it is known that ICG is released from the body through the hepatic system, breastfeeding mothers will be excluded from the study due to the unknown side effects on the infant in the breastfeeding population
* The subject must be able to comply with the study procedures
* All subjects must have the ability to understand the risks, benefits, and alternatives of the study and the willingness to sign a written informed consent

Exclusion Criteria

* Subject has significant liver disease, cirrhosis or liver insufficiency with abnormal liver function tests, as total bilirubin greater than 1.5 X normal and/or serum glutamic oxaloacetic transaminase (SGOT) greater than 2 X normal
* Subject has uremia, serum creatinine greater than 2.0 mg/dl
* Subject has previous history of adverse reaction or allergy to ICG, iodine, shellfish or iodine dyes
* Subject in whom the use of x ray dye or ICG is contraindicated including development of adverse events when previously or presently administered
* Subject has any medical condition, which in the judgment of the Investigator and/or designee makes the subject a poor candidate for the investigational procedure
* Subject is actively participating in another drug, biologic and/or device protocol
* The presence of medical conditions contraindicating general anesthesia or standard surgical approaches
* Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute (NCI)

NIH

Sponsor Role collaborator

City of Hope Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clayton Lau, MD

Role: PRINCIPAL_INVESTIGATOR

City of Hope Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

City of Hope Medical Center

Duarte, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCI-2011-00067

Identifier Type: REGISTRY

Identifier Source: secondary_id

10155

Identifier Type: -

Identifier Source: org_study_id